Nathalie Esser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8054017/publications.pdf

Version: 2024-02-01

		933447	940533
18	2,063	10	16
papers	citations	h-index	g-index
18	18	18	4250
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with $\langle b \rangle \hat{l}^2 \langle b \rangle$ -cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 2022, 322, E307-E318.	3.5	8
2	SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. Journal of Endocrinology, 2021, 248, 95-106.	2.6	12
3	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 2021, 5, bvab084.	0.2	18
4	The \hat{I}^2 Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 2021, 42, 528-583.	20.1	21
5	On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 2021, 64, 2345-2347.	6.3	6
6	New Insights on the PBMCs Phospholipidome in Obesity Demonstrate Modulations Associated with Insulin Resistance and Glycemic Status. Nutrients, 2021, 13, 3461.	4.1	3
7	Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. Journal of Endocrinology, 2021, 251, 125-135.	2.6	O
8	Low concentration IL- $1\hat{l}^2$ promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 2020, 63, 2385-2395.	6.3	10
9	Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 2020, 63, 2007-2021.	6.3	94
10	RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein Engineering, Design and Selection, 2019, 32, 67-76.	2.1	5
11	Neprilysin inhibition: a new therapeutic option for type 2 diabetes?. Diabetologia, 2019, 62, 1113-1122.	6.3	41
12	Saturated fatty acids induce NLRP3 activation in human macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase disruption. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1017-1030.	2.4	61
13	Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Engineering, Design and Selection, 2019, 32, 95-102.	2.1	8
14	Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets, 2018, 10, 175-180.	1.8	18
15	Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice, 2014, 105, 141-150.	2.8	1,420
16	Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochemical Pharmacology, 2014, 92, 131-141.	4.4	134
17	Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 2013, 56, 2487-2497.	6.3	202
18	Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in Endocrinology, $0,13,\ldots$	3.5	2